Clenziderm Daily Care Foaming Cleanser

Description

OBAGI™ MEDICAL CLENZIderm M.D.® Daily Care Foaming Cleanser is an acne treatment formulation containing 2% salicylic acid. This product is designed to provide effective cleansing while targeting acne. It is available in a dosage form of 4 fluid ounces (118 mL). The foaming cleanser is specifically formulated to help clear and prevent acne breakouts.

Uses and Indications

This drug is indicated for the treatment of acne. It effectively dries up acne pimples and helps prevent the formation of new acne pimples.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be cleansed thoroughly before application. A thin layer of the product is to be applied and rinsed off completely. Initial treatment should begin with one application per day. Depending on the patient's response and as directed by a healthcare professional, the frequency may be gradually increased to two or three times daily.

It is important to monitor for signs of excessive drying of the skin. If bothersome dryness or peeling occurs, the application frequency should be reduced to once daily or every other day to mitigate these effects.

Contraindications

There are no specified contraindications for this product. However, it is advised to discontinue use and consult a healthcare professional if severe irritation occurs. Additionally, contact with the eyes should be avoided; in the event of contact, rinse thoroughly with water. The use of this product concurrently with other topical acne medications may increase the likelihood of skin irritation and dryness. Therefore, it is recommended to use only one topical acne medication at a time to minimize the risk of adverse effects.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to avoid contact with the eyes. In the event that the product comes into contact with the eyes, it is imperative to rinse thoroughly with water to mitigate potential irritation.

When utilizing this product, there is an increased risk of skin irritation and dryness, particularly if another topical acne medication is used concurrently. It is recommended that patients use only one topical acne medication at a time to minimize the likelihood of irritation. Should severe irritation occur, patients must discontinue use and consult a healthcare provider for further evaluation and guidance.

This product should be kept out of reach of children. In cases of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is advised without delay.

Side Effects

Patients using this product should be aware that it is for external use only. Contact with the eyes should be avoided; in the event that the product comes into contact with the eyes, it is recommended to rinse thoroughly with water.

Skin irritation and dryness are common adverse reactions, particularly if the product is used concurrently with another topical acne medication. In such cases, the likelihood of irritation increases. Should irritation become severe, patients are advised to discontinue use and consult a healthcare professional.

Additionally, this product should be kept out of reach of children. If ingested, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Drug Interactions

Concurrent use of topical acne medications may increase the risk of skin irritation and dryness. It is advisable to limit the use of topical acne treatments to one at a time to minimize the potential for adverse effects. If irritation occurs, the patient should discontinue the use of additional topical acne medications and consult a healthcare professional for further guidance.

Packaging & NDC

Below are the non-prescription pack sizes of Clenziderm Daily Care Foaming Cleanser (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely to ensure the medication is kept out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is advised.

For topical application, it is recommended to initiate treatment with one application daily. Depending on the patient's response and as directed by a healthcare professional, the frequency may be gradually increased to two or three times daily. Care should be taken to observe for excessive drying of the skin; if bothersome dryness or peeling occurs, the application frequency should be reduced to once a day or every other day.

Geriatric Use

There is no specific information regarding the use of Clenziderm Daily Care Foaming Cleanser in geriatric patients. The prescribing information does not provide details on dosage adjustments, safety concerns, or special precautions that may be necessary for elderly patients. Therefore, healthcare providers should exercise clinical judgment when considering the use of this product in the geriatric population, taking into account the individual patient's health status and any potential risks associated with its use. Monitoring for any adverse effects is advisable, as with any treatment in elderly patients.

Pregnancy

There are no specific warnings or precautions regarding the use of CLENZIDERM DAILY CARE FOAMING CLEANSER during pregnancy. The available data does not indicate whether the product is contraindicated in pregnancy or if there are any associated risks to the fetus. Healthcare professionals should consider the absence of documented risks when advising pregnant patients on the use of this product. However, as with any medication or topical treatment, it is advisable for women of childbearing potential to consult with their healthcare provider before use.

Lactation

There are no specific warnings or recommendations regarding nursing mothers or lactation in the provided text. Therefore, healthcare professionals should consider the absence of data when advising lactating mothers about the use of this medication. It is advisable to monitor breastfed infants for any potential effects, although no specific information is available.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdosage, immediate medical assistance is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical help or contact a Poison Control Center without delay.

Prompt intervention is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific substance involved; therefore, a thorough assessment by a medical professional is recommended to determine the appropriate course of action.

Management procedures may include supportive care and symptomatic treatment, tailored to the individual patient's needs. It is imperative that healthcare providers remain vigilant and prepared to address any complications that may arise from an overdosage scenario.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available for SPL code 90375-7.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children. Instruct patients that if the product is swallowed, they should seek medical help or contact a Poison Control Center immediately.

Patients should be informed to stop using the product and consult a doctor if they experience severe irritation. When using this product, it is essential to avoid contact with the eyes. In the event that the product comes into contact with the eyes, patients should rinse thoroughly with water.

Additionally, healthcare providers should caution patients that skin irritation and dryness may be more likely to occur if they are using another topical acne medication simultaneously. If irritation does occur, patients should be advised to use only one topical acne medication at a time to minimize the risk of adverse effects.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available upon request. It is essential to store the product away from heat and direct sunlight to maintain its integrity. The recommended storage conditions are at a controlled room temperature, specifically between 15°C and 25°C (59°F and 77°F). Proper handling and storage are crucial to ensure the product's efficacy and safety.

Additional Clinical Information

The route of administration for the medication is topical. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Clenziderm Daily Care Foaming Cleanser, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)